Connecticut State Hospital's entire resident population (n=1,300) was screened on an arbitrary target day to determine eligibility for clozapine.
Sixty percent of 803 patients with schizophrenia or schizoaffective disorder diagnoses met Food and Drug Administration (FDA) - approved criteria for clozapine use as judged by review of past medication trial records and by the responsible physician.
Eighty-eight percent of these patients were medically cleared, and of those cleared, 63 percent agreed to clozapine treatment.
Of the patients who began a clozapine trial, 76 percent were still taking the drug 12 months later.
Preliminary findings from a randomized trial of clozapine versus usual care (n=227) indicate that discharge rates associated with clozapine and usual care do not differ.
Once discharged, however, patients assigned to clozapine are less likely to be readmitted.
Hence, clozapine may be more cost-effective than usual care.
However, before savings can be realized, State governments will have to make up-front investments of approximately $140 million simply to give patients hospitalized on a single day a year's access to clozapine.
Mots-clés Pascal : Schizophrénie, Psychose schizoaffective, Psychose, Critère, Choix, Chimiothérapie, Traitement, Clozapine, Neuroleptique, Psychotrope, Hôpital, Evolution, Sortie hôpital, Economie santé, Analyse coût, Homme, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Schizophrenia, Schizoaffective psychosis, Psychosis, Criterion, Choice, Chemotherapy, Treatment, Neuroleptic, Psychotropic, Hospital, Evolution, Hospital discharge, Health economy, Cost analysis, Human, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0197722
Code Inist : 002B02B03. Création : 199608.